

ATTR Amyloidosis Treatment Market is Estimated to Witness High Growth Owing to Market Growth Strategaa

The ATTR amyloidosis treatment market encompasses a range of novel therapeutics designed to target transthyretin protein misfolding and aggregation, offering significant advantages over traditional supportive care. Product offerings include TTR stabilizers, gene silencers, and RNA-based therapies that address both hereditary and wild-type forms of ATTR amyloidosis. These treatments improve patient quality of life by reducing cardiomyopathy progression, neuropathic pain, and organ dysfunction, while lowering hospitalization rates and overall healthcare costs. Growing awareness among healthcare professionals, coupled with robust market research and expanded diagnostic capabilities, is driving earlier diagnosis and treatment initiation.

[ATTR](#)

[Amyloidosis Treatment Market](#) industry size expands, pharmaceutical companies are leveraging advanced drug delivery platforms and precision medicine approaches to overcome market challenges such as variable patient responses and high therapy costs. Market insights suggest that increasing investment in R&D, strategic partnerships, and regulatory approvals will further propel pipeline maturation. Moreover, the rising prevalence of age-related wild-type ATTR amyloidosis and expanding indications for polyneuropathy are creating new market opportunities for innovative therapies. With competitive dynamics shaped by key players focusing on market share consolidation and strategic licensing.

The ATTR

amyloidosis treatment market is estimated to be valued at USD 4.14 Bn in 2025 and is expected to reach USD 7.52 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.9% from 2025 to 2032.

Key Takeaways

Key players operating in the ATTR Amyloidosis Treatment Market are

- Pfizer Inc., Alnylam Pharmaceuticals, Inc.,
- Ionis Pharmaceuticals, Inc.,
- Eidos Therapeutics, Inc.,
- Akcea Therapeutics, Inc.

